Poly MedicureQ3 FY24

Poly Medicure Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,649.6P/E: 53.0Market Cap: ₹16.8K CrSector: Healthcare Equipment & Supplies

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2
  • The company targets a 20% growth in revenue for the next year, starting with a moderate estimate to revise upward after Q1 or early Q2.
  • Domestic business is expected to grow around 22%-23%, driven by deeper market penetration and expansion of new divisions including renal, cardiology, and critical care.
  • Renal segment projected to scale up sharply with an anticipated 50% growth next year, compared to 22% growth this year.
  • Export business, especially Europe which accounts for ~40% of export revenues, is showing strong growth (40%+).
  • US market entry underway with expected revenue buildup to $15-20 million annually by FY28.
  • Overall, exports have grown by ~23.5% in nine months, domestic by ~18.5%.
  • Increasing salesforce in India by ~100 people per year to boost productivity and coverage (5,000+ hospitals covered currently).
  • New manufacturing plants and capacity expansions aim for full utilization by year-end, supporting scaling volumes and revenue growth.

See what Poly Medicure management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no explicit mention of plans for new fundraising through debt or equity in the provided transcript.
  • The company is currently in a high capex cycle, having spent around INR 185 crores in the first 9 months, with plans to spend up to INR 230-240 crores this financial year and INR 100-150 crores next year.
  • The company has a high cash balance on its balance sheet (over INR 150 crores) and strong operating cash flows.
  • The focus appears to be on utilizing internal accruals for ongoing capex and growth rather than raising new funds externally.
  • The company is also looking at potential inorganic opportunities in the future, but no specific mention of equity or debt fundraising linked to those was made.

See what Poly Medicure management said on order book — free account, 30 seconds.

Capex plans

Yes
  • In the first 9 months, Poly Medicure has spent around INR 185 crores on capex and expects to exceed this with a total of INR 230-240 crores for the full year.
  • Four new plants: 2 already operational in Faridabad, 1 in Jaipur SEZ, and 1 under final stages of construction to be ready by early next financial year (April-May).
  • Next year, additional capex of INR 100-150 crores planned to add more equipment and machines.
  • New plants currently operating at 30-40% utilization; full ramp-up expected by end of the year.
  • Capex focused on expanding manufacturing capacity for existing and new divisions such as renal, critical care, and cardiology.
  • Plans for setting up own gamma sterilization facility to reduce dependence on external vendors.
  • Looking at possible inorganic opportunities after current capex cycle tapers down.

Track Poly Medicure — get its next earnings analysis in your feed

How does Poly Medicure rank vs peers in Healthcare Equipment & Supplies?

Pro feature
ThisPoly Medicure
Rev 2Mar 3

How does Poly Medicure rank in Healthcare Equipment & Supplies?

Compare Poly Medicure against every Healthcare Equipment & Supplies company (Q3 FY24) on revenue, margins and earnings-call signals.

View Healthcare Equipment & Supplies leaderboard →

Others in Healthcare Equipment & Supplies this season

  • Fischer Medical (Q2 FY27)

    For the quarter ended September 30, 2026, the Standalone revenue from operations was ₹27.62 Lakhs compared to ₹742.69 Lakhs in Q2 FY 2025, showing a…

  • Mohini Health (Q2 FY27)

    Revenue from operations for the half year ended 30th Sept 2026 is ₹11,043.00 lakhs, compared to ₹7,353.87 lakhs for the half year ended 30th Sept 2025, showing…

  • Aprameya Enginee (Q2 FY27)

    216.21 lakhs, up 97% year-on-year (YoY). Key results statement takeaways from Aprameya Engineering Ltd's Q2 FY27 results statement — and how it ranks against se

  • QMS Medical (Q2 FY27)

    4,470.00 lakhs in Q2 2025), a year-on-year increase of approximately 17.5% . Key results statement takeaways from QMS Medical Allied Services Ltd's Q2 FY27 resu

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →